Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37463 | 0.90 | IDO1 (0.70) | IDO1AKR1C3LOXL2TSHRRAB9A | |
| SCHEMBL15114767 | 0.87 | IDO1 (0.58) | IDO1AKR1C3LOXL2TSHRRAB9A | |
| SCHEMBL6141174 | 0.84 | IDO1 (0.63) | IDO1AKR1C3LOXL2TSHRRAB9A | |
| SCHEMBL6141206 | 0.84 | IDO1 (0.54) | IDO1AKR1C3LOXL2TSHRRAB9A | |
| SCHEMBL7087223 | 0.82 | IDO1 (0.61) | IDO1AKR1C3LOXL2TSHRRAB9A | |
| SCHEMBL3935764 | 0.82 | IDO1 (0.61) | IDO1AKR1C3LOXL2TSHRRAB9A | |
| SCHEMBL3935769 | 0.82 | IDO1 (0.61) | IDO1AKR1C3LOXL2TSHRRAB9A | |
| SCHEMBL3157211 | 0.82 | IDO1 (0.61) | IDO1AKR1C3LOXL2TSHRRAB9A | |
| SCHEMBL7027123 | 0.82 | IDO1 (0.61) | IDO1AKR1C3LOXL2TSHRRAB9A | |
| SCHEMBL7032223 | 0.82 | IDO1 (0.61) | IDO1AKR1C3LOXL2TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-02-16 | — | — | US | claimed |
| WO-2021216722-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2021-10-28 | — | — | WO | claimed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| CN-113784721-B | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | AGENSYS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3581206-B1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE P13K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2007123763-A2 | ARTICLES HAVING LOCALIZED MOLECULES DISPOSED THEREON AND METHODS OF PRODUCING SAME | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070238679-A1 | Articles having localized molecules disposed thereon and methods of producing same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| WO-2006136309-A1 | CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060173172-A1 | Method for producing novel spinosyn derivatives | JESCHKE PETER | 2006-08-03 | — | — | US | disclosed |
| US-7034130-B2 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2006-04-25 | — | — | US | disclosed |
| EP-1412346-B1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2005-03-09 | — | — | EP | disclosed |
| US-20040242858-A1 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1412346-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | Bayer CropScience AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003010155-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | IDO1 3931/4885AKR1C3 3599/4885LOXL2 4834/4885 |
| US-20060173172-A1 | Method for producing novel spinosyn derivatives | COX15, SYVN1, CYP51A1 | IDO1 2418/4885AKR1C3 213/4885LOXL2 676/4885 |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, CA12, H1-10 | IDO1 1703/4885AKR1C3 3373/4885LOXL2 4676/4885 |
| US-20040242858-A1 | Method for producing novel spinosyn derivatives | COX15, SYVN1, CYP51A1 | IDO1 2418/4885AKR1C3 213/4885LOXL2 676/4885 |
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | IDO1 1637/4885AKR1C3 2273/4885LOXL2 3658/4885 |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | NUDT1, PNP, ITPA | IDO1 2727/4885AKR1C3 2132/4885LOXL2 4811/4885 |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | TMED10, CD44, CA12 | IDO1 2624/4885AKR1C3 3920/4885LOXL2 4682/4885 |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, ARID2, DYNLL2 | IDO1 1376/4885AKR1C3 3248/4885LOXL2 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.